Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world…
Articles by Steve Bryson PhD
The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective…
An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active…
Ankylosing spondylitis (AS) patients undergoing total hip replacement face longer hospital stays and higher related costs than other patients…
People with ankylosing spondylitis (AS) are at a significantly higher risk of stroke — a 56% greater risk —…
The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including…
Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the…
One year of UCB Biopharm‘s investigational therapy bimekizumab, administered subcutaneously (under the skin) once every four weeks, resulted…
People with ankylosing spondylitis (AS) who experience uveitis, an inflammatory condition of the eye, have a significantly higher risk…
Almost all people with axial spondyloarthritis (axSpA) who had worsening disease severity after stopping Taltz (ixekizumab) saw improvements after…